Cancer Research

Prescient Therapeutics demystifies OmniCAR’s ‘on-demand tumour killing’ capabilities

Prescient Therapeutics’ next-generation CAR-T platform OmniCAR has delivered overwhelmingly positive results in recent studies as the company builds

October 20, 2021 0 Comments

Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke and Director of Scientific Affairs, Rebecca Lim, present a special ‘OmniCAR

October 19, 2021

Dr Rebecca Lim, Director of Scientific Affairs at Prescient Therapeutics (ASX: PTX), presented at the fifth annual Cell

October 13, 2021 0 Comments

Dr Rebecca Lim, Director of Scientific Affairs at Prescient Therapeutics (ASX: PTX), presented at the fifth annual Cell

September 22, 2021 0 Comments

Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as it advances the

September 1, 2021 0 Comments

Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke, will be joining

August 25, 2021 0 Comments

Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T cells to overcome

August 18, 2021 0 Comments

Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses the encouraging progress through clinical trials of Prescient’s

August 11, 2021

CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have limited patient access.

August 11, 2021 0 Comments

Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers.

August 4, 2021